Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $7.29, up 0.00% on the session, giving a market capitalisation of $53.9M. On trailing twelve-month figures it carries a trailing P/E of -1.18, a net margin of 0.0%. Its beta of 0.41 implies it has historically moved less than the broad market.
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences, Inc. is most often compared with the following Healthcare names: